Citations

Mayo Clinic

Showing 10 of 108537 citations.

Updates on the Management of Colorectal Cancer in Older Adults
O'Donnell, C. , Hubbard, Joleen M. , Jin, Zhaohui , O'Donnell, Conor D J , Hubbard, Joleen , Jin, Zhaohui

Cancers | May 10, 2024 | Volume: 16 | Issue: 10 | Pages: 1820

10.3390/cancers16101820 | PMID 38791899 Get It

Colorectal cancer (CRC) poses a significant global health challenge. Notably, the risk of CRC escalates with age, with the majority of cases occurring in those over the age of 65. Despite recent progress in tailoring treatments for early and advanced CRC, there is a lack of prospective data to guide the management of older patients, who are frequently underrepresented in clinical trials. This article reviews the contemporary landscape of managing older individuals with CRC, highlighting recent advancements and persisting challenges. The role of comprehensive geriatric assessment is explored. Opportunities for treatment escalation/de-escalation, with consideration of the older adult’s fitness level. are reviewed in the neoadjuvant, surgical, adjuvant, and metastatic settings of colon and rectal cancers. Immunotherapy is shown to be an effective treatment option in older adults who have CRC with microsatellite instability. Promising new technologies such as circulating tumor DNA and recent phase III trials adding later-line systemic therapy options are discussed. Clinical recommendations based on the data available are summarized. We conclude that deliberate efforts to include older individuals in future colorectal cancer trials are essential to better guide the management of these patients in this rapidly evolving field.
Utilizing median and maximum QTc values improves prediction of breakthrough cardiac events in pediatric long QT syndrome
Rohatgi, Ram K., Tseng, Andrew S. , Sugrue, Alan , Lee, Alexander T. , Wackel, Phillip L., Cannon, Bryan C. , Bos, J. Martijn , Ackerman, Michael J. , Sugrue, Alan , Wackel, Philip , Ackerman, Michael J , Tseng, A S , Bos, Johan M , Scott, Christopher G.

Journal of Cardiovascular Electrophysiology | May 10, 2024 | Volume: 35 | Issue: 7 | Pages: 1370-1381

10.1111/jce.16293 | PMID 38725227 Get It

AbstractIntroductionAlthough prior studies indicate that a QTc > 500 ms on a single baseline 12‐lead electrocardiogram (ECG) is associated with significantly increased risk of arrhythmic events in long QT syndrome (LQTS), less is known about the risk of persistent QT prolongation. We sought to determine QTc persistence and its prognostic effect on breakthrough cardiac events (BCEs) among pediatric patients treated for LQTS.MethodsWe performed a retrospective analysis of 433 patients with LQTS evaluated, risk‐stratified, and undergoing active guideline‐based LQTS treatment between 1999 and 2019. BCEs were defined as arrhythmogenic syncope/seizure, sudden cardiac arrest (SCA), appropriate VF‐terminating ICD shock, and sudden cardiac death (SCD).ResultsDuring the median follow‐up of 5.5 years (interquartile range [IQR] = 3–9), 32 (7%) patients experienced a total of 129 BCEs. A maximum QTc threshold of 520 ms and median QTc threshold of 490 ms were determined to be strong predictors for BCEs. A landmark analysis controlling for age, sex, genotype, and symptomatic status demonstrated models utilizing both the median QTc and maximum QTc demonstrated the highest discriminatory value (c‐statistic = 0.93–0.95). Patients in the high‐risk group (median QTc > 490 ms and maximum QTc > 520 ms) had a significantly lower BCE free survival (70%–81%) when compared to patients in both medium‐risk (93%–97%) and low‐risk (98%–99%) groups.ConclusionsThe risk of BCE among patients treated for LQTS increases not only based upon their maximum QTc, but also their median QTc (persistence of QTc prolongation). Patients with a maximum QTc > 520 ms and median QTc > 490 ms over serial 12‐lead ECGs are at the highest risk of BCE while on guideline‐directed medical therapy.
Trends and disparities in cardiac implantable electronic device infection‐related mortality in the United States
Munir, Muhammad Bilal , Deshmukh, Abhishek , DeSimone, Christopher V. , Agarwal, Siddharth , Deshmukh, Abhishek J , DeSimone, Christopher V , Munir, Muhammad Bilal , Agarwal, Siddharth , Agarwal, Siddharth, Qamar, Usama , Asad, Zain Ul Abideen , DeSimone, Daniel C.

Journal of Cardiovascular Electrophysiology | May 10, 2024 | Volume: 35 | Issue: 7 | Pages: 1487-1489

10.1111/jce.16298 | PMID 38725220 Get It

AbstractIntroductionWe performed a cross‐sectional study using the Centers for Disease Control and Prevention's (CDC's) Wide‐Ranging Online Data for Epidemiologic Research (WONDER) database to analyze the trends in cardiac implantable electronic device (CIED) infection‐related mortality from 1999 to 2020.MethodsWe analyzed the death certificate data from the CDC WONDER database from 1999 to 2020 for CIED infections in the US population aged ≥25 years using International Classification of Diseases, Tenth Revision (ICD‐10) codes, listed as the underlying or contributing cause of death. Age‐adjusted mortality rates (AAMR) and 95% confidence intervals (CIs) were computed per 1 million population by standardizing crude mortality rates to the 2000 US census population. To assess annual mortality trends, we employed the Joinpoint regression model, calculating the annual percent change (APC) in AAMR and corresponding 95% CIs.ResultsOverall, there was an observed declining trend in AAMRs related to CIED infection‐related mortality. Males accounted for 55% of the total deaths, with persistently higher AAMRs compared to females over the study duration. Both males and females had an overall decreasing trend in AAMRs throughout the study duration. On race/ethnicity stratified analysis, non‐Hispanic (NH) Blacks exhibited the highest overall AAMR, followed by NH American Indians or Alaska Natives, NH Whites, Hispanic or Latinos, and NH Asian or Pacific Islanders. On a stratified analysis based on region, the South region had the highest overall AAMR, followed by the Midwest, West, and Northeast regions.ConclusionOur study demonstrates a significant decline in CIED infection‐related mortality in patients over the last two decades. Notable gender, racial/ethnic, and regional differences exist in the rates of mortality related to CIED infections.
Primary Human Papillomavirus Test Uptake and Cervical Cancer Screening Trends in the Midwest, United States
Ehman, Katie M., Jenkins, Gregory D. , Grimm, Jessica A. , Cammack, Taylor L., Samuelson, Brittanee J. , Stoll, Rebecca , Maxson, Julie, MacLaughlin, Kathy L. , Stoll, Rebecca J, Maxson, Julie A, Grimm, Jessica A

Journal of Primary Care & Community Health | May 10, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319241251934 | PMID 38726652 Get It

Introduction/Objectives: Despite U.S. Preventive Services Task Force and American Cancer Society endorsement of primary HPV screening, limited published data shows low uptake. Primary Aim: Assess cervical cancer screening rates over time, particularly primary HPV test uptake, among patients in a midwestern practice. Secondary Aim: Evaluate associations between sociodemographics and screening adherence. Methods: Cross-sectional study. Qualifying subjects and type of screening test used were identified by applying ICD-9, ICD-10, lab test, and CPT codes to the Unified Data Platform. Sociodemographics were found through the electronic health record. Results: Primary HPV uptake represented <1% of annual screening from 1/2017 to 1/2022. On 1/1/2022, only 55% of 21 to 29 year old and 63% of 30 to 65 year old were up to date with screening among the studied population. For 21 to 29 year old, compared with White women, Black women were 28% less likely to be screened [RR = 0.72 (0.66-0.79)]. Compared with never-smokers, current smokers were 9% less likely to be screened [RR = 0.91 (0.87-0.96)], past smokers were 14% more likely [RR = 1.14 (1.09-1.2)]. Among 30 to 65 year old, compared with White women, Black women were 14% less likely to be screened [RR = 0.86 (0.81-0.9)]. Compared with never-smokers, current smokers were 21% less likely to be screened [RR = 0.79 (0.77-0.81)], past smokers were 6% less likely [RR = 0.94 (0.92-0.95)]. Jointly considering race, ethnicity, smoking status, Charlson score, and rurality, findings were similar for 21 to 29 year old; Black women were screened less than White women [RR = 0.73 (0.67-0.79)]; current smokers [RR = 0.9 (0.85-0.94)] and past smokers [RR = 1.12 (1.06-1.17)] were screened less than never smokers. For 30 to 65 year old, Black women were screened less than White women [RR = 0.83 (0.79-0.88)]; current smokers [RR = 0.8 (0.78-0.81)] and past smokers [RR = 0.95 (0.93-0.96)] were screened less than never smokers. Conclusions: Screening rates remained below the Healthy People 2030 goal of 79.2% over time, particularly for younger Black women and current smokers, with minimal use of primary HPV screening.
Clostridioides Difficile: A Concise Review of Best Practices and Updates
Yakout, Abdelrahman , Bi, Yan , Harris, Dana M. , Harris, Dana M

Journal of Primary Care & Community Health | May 10, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319241249645 | PMID 38726585 Get It

Clostridioides difficile infection (CDI) is one of the most common and severe nosocomial infections worldwide. It can also affect healthy individuals in the community. The incidence of CDI has been on the rise globally for the past decade, necessitating a proactive approach to combat its spread; new strategies are being developed to enhance diagnostic accuracy and optimize treatment outcomes. Implementing the 2-step testing has increased diagnostic specificity, reducing the usage of CD-specific antibiotics with no concomitant increase in surgical complication rates. In 2021, the Infectious Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/SHEA) shifted its preference for initial treatment to fidaxomicin over vancomycin and metronidazole due to its lower recurrence rate. It also prioritized fidaxomicin for the treatment of recurrent CDI. There are new developments on the frontiers of fecal microbiota therapies, with RBX2660 and SER-109 approved recently by the FDA for prevention, with other microbiome-based therapies in various development and clinical trials. This review offers providers an updated and practical guide for CDI management.
Implementation of a geriatric assessment SmartPhrase: A multi‐institutional pilot study
Zuo, Jessica X., Szymanski, Eva P., Fessler, Emily, Chippendale, Ryan , Ouellet, Jennifer A. , Schecter, Leah, Zuo, Xi, Xie, Dawei , Marottoli, Richard A. , Miller, Rachel , Chippendale, Ryan Z

Journal of the American Geriatrics Society | May 10, 2024 | Volume: 72 | Issue: 7 | Pages: 2281-2284

10.1111/jgs.18951 | PMID 38725391 Get It

Long-term Effects of COVID-19 on Vascular Parameters—A Prospective Longitudinal Ultrasound Clinical Study
Chen, James , Smith, Kane , Xu, Qian , Ali, T’shura , Cavallazzi, Rodrigo , Clifford, Sean P., Arnold, Forest W. , Huang, Jiapeng , Smith, Kane, Ghafghazi, Shahab , Kong, Maiying , Huang, Jiapeng

Journal for Vascular Ultrasound | May 10, 2024 | Volume: 48 | Issue: 2 | Pages: 95-102

10.1177/15443167231210357 | PMID 39641110 Get It

Objective: To investigate the longitudinal effects of COVID-19 on major vascular structures and parameters and clinical outcomes. Design: Observational prospective trial. Setting: Post-COVID-19 research clinic established by University of Louisville Division of Infectious Diseases. Participants: The study population consisted of 72 post-COVID-19 individuals and 11 non-COVID-19 infected participants in the control group. The participants were recruited from adult hospitals and from the community. The enrollment started in October 2020 and follow-up periods were at 3, 6, and 12 months from their initial COVID-19 diagnosis. Interventions: The participants were interviewed for medical and COVID-19 infection history. Samples of white blood cell (WBC), C-reactive protein (CRP), and D-dimer were taken at each visit. Certified sonographers performed vascular ultrasound on the study participants. Measurements and Main Results: Median intima-media thickness (IMT) was increased in mild/asymptomatic (0.80 mm) and severe/critical (0.90 mm) groups when compared with controls (0.60 mm; P < .001 for both groups). In the asymptomatic/mild group, 6-month median IMT (0.88 mm) was increased, compared with the 3-month group (0.75 mm), with P = .026. Increased age was associated with decreased mean arterial blood velocities (cm/s): common carotid ( r = −0.236, P = .032), internal carotid ( r = −0.208, P = .048), and subclavian artery mean velocity ( r = −0.357, P = .003). We did not find any instance of deep vein thrombosis. Median D-dimer, CRP, and WBC in the control group differed from asymptomatic/mild COVID-19 group ( P = .026, .011, and .003, respectively). Moreover, WBC in the asymptomatic/mild group and moderate COVID-19 group differed from severe/critical group ( P = .025 and P = .027, respectively); CRP also differed between asymptomatic/mild group and severe/critical group ( P = .014). Conclusions: There were differences in intima-media lumen thickness (IMT), arterial velocities, and inflammatory markers in post-COVID-19 patients. There was no instance of deep vein thrombosis in this post-COVID-19 study cohort. The increased IMT might infer atherosclerosis, which has shown to increase cardiovascular risks. It is not yet known whether the increase in IMT due to COVID should be treated in the same way as non-COVID-19 atherosclerosis—through statins, for example—or whether regular cardiovascular risk reduction would be useful. Clinical trial and mechanistic studies should be performed to further our understanding of COVID-19-related vascular pathologies.
European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency
Beuschlein, Felix , Else, Tobias , Hamidi, Oksana , Hulsteijn, Leonie T. van , Karavitaki, Niki , Prete, Alessandro , Vaidya, Anand , Yedinak, Christine, Dekkers, Olaf M, Bancos, Irina , Hamidi, Oksana , van Hulsteijn, Leonie , Vaidya, Anand , Karavitaki, Niki , Prete, Alessandro , Beuschlein, Felix , Bancos, Irina , Hahner, Stefanie , Husebye, Eystein Sverre , Dekkers, Olaf M.

The Journal of Clinical Endocrinology & Metabolism | May 9, 2024 | Volume: 109 | Issue: 7 | Pages: 1657-1683

10.1210/clinem/dgae250 | PMID 38724043 Get It

Abstract Glucocorticoids are widely prescribed as anti-inflammatory and immunosuppressive agents. This results in at least 1% of the population using chronic glucocorticoid therapy, being at risk for glucocorticoid-induced adrenal insufficiency. This risk is dependent on the dose, duration and potency of the glucocorticoid, route of administration, and individual susceptibility. Once glucocorticoid-induced adrenal insufficiency develops or is suspected, it necessitates careful education and management of affected patients. Tapering glucocorticoids can be challenging when symptoms of glucocorticoid withdrawal develop, which overlap with those of adrenal insufficiency. In general, tapering of glucocorticoids can be more rapidly within a supraphysiological range, followed by a slower taper when on physiological glucocorticoid dosing. The degree and persistence of HPA axis suppression after cessation of glucocorticoid therapy are dependent on overall exposure and recovery of adrenal function varies greatly amongst individuals. This first European Society of Endocrinology/Endocrine Society joint clinical practice guideline provides guidance on this clinically relevant condition to aid clinicians involved in the care of patients on chronic glucocorticoid therapy.
Teaching NeuroImage: Fundoscopic and Optical Coherence Tomography Changes in Primary CNS Lymphoma
Moheb, Negar , Olsen, Timothy W. , Chen, John J. , Chen, John J , Tobin, W. Oliver

Neurology | May 9, 2024 | Volume: 102 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000209512 | PMID 38723229 Get It

Genetic testing in early-onset atrial fibrillation
Kany, Shinwan , Jurgens, Sean J. , Rämö, Joel , Rienstra, Michiel , Chung, Mina K. , Ackerman, Michael J. , McNally, Elizabeth M. , Semsarian, Christopher , Wilde, Arthur A.M., Roden, Dan M. , Shoemaker, M. Benjamin , Rienstra, Michiel , Ackerman, Michael J , McNally, Elizabeth M , Semsarian, Christopher , Schnabel, Renate B , Benjamin, Emelia J , Kirchhof, Paulus , Roden, Dan M. , Ellinor, Patrick T , Jurgens, Sean J , Christophersen, Ingrid Elisabeth , Olesen, Morten S. , Schnabel, Renate B. , Benjamin, Emelia J. , Rehm, Heidi L. , Kirchhof, Paulus , Bezzina, Connie R. , Ellinor, Patrick T.

European Heart Journal | May 9, 2024 | Volume: 45 | Issue: 34 | Pages: 3111-3123

10.1093/eurheartj/ehae298 | PMID 39028637 Get It

Abstract Atrial fibrillation (AF) is a globally prevalent cardiac arrhythmia with significant genetic underpinnings, as highlighted by recent large-scale genetic studies. A prominent clinical and genetic overlap exists between AF, heritable ventricular cardiomyopathies, and arrhythmia syndromes, underlining the potential of AF as an early indicator of severe ventricular disease in younger individuals. Indeed, several recent studies have demonstrated meaningful yields of rare pathogenic variants among early-onset AF patients (∼4%–11%), most notably for cardiomyopathy genes in which rare variants are considered clinically actionable. Genetic testing thus presents a promising opportunity to identify monogenetic defects linked to AF and inherited cardiac conditions, such as cardiomyopathy, and may contribute to prognosis and management in early-onset AF patients. A first step towards recognizing this monogenic contribution was taken with the Class IIb recommendation for genetic testing in AF patients aged 45 years or younger by the 2023 American College of Cardiology/American Heart Association guidelines for AF. By identifying pathogenic genetic variants known to underlie inherited cardiomyopathies and arrhythmia syndromes, a personalized care pathway can be developed, encompassing more tailored screening, cascade testing, and potentially genotype-informed prognosis and preventive measures. However, this can only be ensured by frameworks that are developed and supported by all stakeholders. Ambiguity in test results such as variants of uncertain significance remain a major challenge and as many as ∼60% of people with early-onset AF might carry such variants. Patient education (including pretest counselling), training of genetic teams, selection of high-confidence genes, and careful reporting are strategies to mitigate this. Further challenges to implementation include financial barriers, insurability issues, workforce limitations, and the need for standardized definitions in a fast-moving field. Moreover, the prevailing genetic evidence largely rests on European descent populations, underscoring the need for diverse research cohorts and international collaboration. Embracing these challenges and the potential of genetic testing may improve AF care. However, further research—mechanistic, translational, and clinical—is urgently needed.